Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma

Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma

No reliable predictive blood-based biomarkers are available for determining survival from pancreatic adenocarcinoma (PDAC). This combined discovery and validation study examines promoter hypermethylation (ph) of secreted frizzled-related protein 1 (SFRP1) in plasma-derived cell-free DNA as an indepe...

Full description

Bibliographic Details
Main Authors: Benjamin Emil Stubbe, Stine Dam Henriksen, Poul Henning Madsen, Anders Christian Larsen, Henrik Bygum Krarup, Inge Søkilde Pedersen, Martin Nygård Johansen, Ole Thorlacius-Ussing
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
biomarker
cancer
pancreatic cancer
prognostic
survival
blood-based
Online Access:https://www.mdpi.com/2072-6694/13/22/5717

Internet

https://www.mdpi.com/2072-6694/13/22/5717

Similar Items